Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target Raised to $10.00

Amneal Pharmaceuticals (NASDAQ:AMRX) had its price objective raised by Truist Financial from $9.00 to $10.00 in a research note released on Monday morning, Benzinga reports. Truist Financial currently has a buy rating on the stock.

Separately, The Goldman Sachs Group raised their target price on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a buy rating in a research note on Monday, May 6th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of Buy and a consensus price target of $9.00.

Amneal Pharmaceuticals Price Performance

AMRX opened at $7.81 on Monday. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.97 and a current ratio of 1.65. The stock has a market capitalization of $2.41 billion, a PE ratio of -13.95 and a beta of 1.23. The stock’s 50 day moving average price is $7.03 and its 200-day moving average price is $6.34. Amneal Pharmaceuticals has a 52-week low of $3.36 and a 52-week high of $8.15.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several hedge funds have recently modified their holdings of AMRX. Arizona State Retirement System purchased a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at $183,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Amneal Pharmaceuticals in the fourth quarter valued at approximately $187,000. New York State Common Retirement Fund grew its position in Amneal Pharmaceuticals by 149.1% during the fourth quarter. New York State Common Retirement Fund now owns 122,003 shares of the company’s stock valued at $741,000 after buying an additional 73,020 shares during the period. Truist Financial Corp acquired a new stake in Amneal Pharmaceuticals in the 4th quarter valued at $395,000. Finally, Swiss National Bank acquired a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth about $1,291,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.